Bicycle Therapeutics plc (NASDAQ:BCYC) Short Interest Update

Bicycle Therapeutics plc (NASDAQ:BCYC) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,780,000 shares, a growth of 6.1% from the May 31st total of 2,620,000 shares. Based on an average daily trading volume, of 364,600 shares, the short-interest ratio is currently 7.6 days.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BCYC shares. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.86.

Bicycle Therapeutics Trading Down 1.2 %

NASDAQ:BCYC traded down $0.23 on Wednesday, hitting $19.58. 64,364 shares of the stock were exchanged, compared to its average volume of 353,942. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.42 and a current ratio of 10.42. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $27.50. The company’s 50-day moving average price is $22.36 and its 200 day moving average price is $21.62.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.63. Bicycle Therapeutics had a negative return on equity of 49.35% and a negative net margin of 404.14%. The company had revenue of $19.53 million for the quarter, compared to the consensus estimate of $6.06 million. The business’s revenue for the quarter was up 298.9% on a year-over-year basis. On average, equities research analysts forecast that Bicycle Therapeutics will post -4.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Baker BROS. Advisors LP raised its position in shares of Bicycle Therapeutics by 176.1% in the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock valued at $123,076,000 after acquiring an additional 3,152,433 shares during the period. Armistice Capital LLC lifted its holdings in Bicycle Therapeutics by 53.6% during the fourth quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $27,771,000 after acquiring an additional 536,000 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after acquiring an additional 121,613 shares during the period. Polar Capital Holdings Plc increased its holdings in shares of Bicycle Therapeutics by 33.2% in the third quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock worth $20,321,000 after acquiring an additional 252,000 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Bicycle Therapeutics by 12.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 883,105 shares of the company’s stock worth $21,989,000 after purchasing an additional 100,107 shares during the period. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.